Induction-maintenance therapy for HIV-1 infection

Marcel E. Curlin, Timothy Wilkin, John Mittler

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Recent clinical trials have renewed interest in treating HIV-1 infection through the use of induction-maintenance regimens, a strategy commonly used for the treatment of TB and certain hematopoeitic malignancies. In these conditions, the common element underlying success has been the ability of induction regimens to reduce therapy-resistant pathogens to levels that can be controlled using a maintenance regimen. The success of recent clinical trials of induction-maintenance therapy for HIV-1 suggests that this concept could have a variety of applications, such as reducing toxicities, reducing treatment costs and improving the treatment of salvage patients. However, current induction-maintenance protocols have not fully capitalized on available quantitative data concerning pharmacokinetics and pharmacodynamics, viral replication dynamics, viral latency and the evolution of drug resistance. In this review, we reason that it should be possible to improve success rates of induction-maintenance and other innovative, therapeutic strategies using mathematical models that account for this information.

Original languageEnglish (US)
Pages (from-to)175-185
Number of pages11
JournalFuture HIV Therapy
Volume2
Issue number2
DOIs
StatePublished - Sep 29 2008

    Fingerprint

Keywords

  • AIDS
  • Antiretroviral drugs
  • Drug resistance
  • Drug therapy
  • HIV-1
  • Induction-maintenance
  • Mathematical model

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Virology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this